BUZZ - Johnson & Johnson shares decline as strong earnings are overshadowed by weak medical device sales

Latest Updates

October 13 - ** Johnson & Johnson (JNJ.N) shares fell by 4.4%, closing at $252.38

** Johnson & Johnson’s medical technology business sales grew by 2.5% to $8.6 billion in the third quarter, but did not meet analysts’ expectations of $8.71 billion — LSEG

** Overall, third-quarter adjusted earnings per share were $2.59, above expectations of $2.54; revenue was $25.4 billion, surpassing expectations of $25.28 billion — LSEG

** “While overall performance was broadly in line with expectations, we believe investors will be disappointed by certain details in the results,” Guggenheim analyst Vamil Divan noted, adding that the performance of the medical technology business was “somewhat disappointing”

** The company raised its 2026 performance outlook (link), now expecting reported sales of about $101.2 billion and median adjusted earnings per share of $11.10, whereas previous estimates were about $101.1 billion and $11.04, respectively

** Analysts’ average estimate for 2026 sales is about $101.3 billion, with adjusted earnings per share of $11.08, according to LSEG data

** As of the close of the previous trading day, Johnson & Johnson (JNJ) had risen 27.4% for the year, outperforming the S&P 500 Index .SPX gain of 11.7%

(To assist non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides these solely for reader convenience. Reuters assumes no responsibility for any damage or loss resulting from the use of automated translation functions.)